新型抗凝药物及其治疗静脉血栓栓塞症的临床应用

doi:10.3969/j.issn.1004-583X.2016.04.002

临床荟萃 ›› 2016, Vol. 31 ›› Issue (4): 352-354.doi: 10.3969/j.issn.1004-583X.2016.04.002

新型抗凝药物及其治疗静脉血栓栓塞症的临床应用

杨媛华¹, 杨苏乔¹, 张明园²

1.首都医科大学附属北京朝阳医院呼吸与危重症医学科,北京呼吸疾病研究所,北京 100020;
2.天津市海河医院呼吸科,天津 300350

收稿日期:2016-01-15 出版日期:2016-04-05 发布日期:2016-04-18
通讯作者: 杨媛华,Email:yyh1031@sina.com
作者简介:杨媛华，医学博士，主任医师，副教授，硕士研究生导师。中华医学会呼吸病学分会肺栓塞学组委员。长期从事呼吸系统疾病的临床、教学和科研工作，主要研究方向为肺栓塞和肺动脉高压的诊断与治疗。在相关领域参与完成包括国家科技攻关、科技支撑计划等多项课题的研究。
基金资助:
国家“十二五”科技支撑计划课题(2011BAI11B17,2012BA105B00)

New anticoagulants and clinical application of venous thromboembolism

Yang Yuanhua¹, Yang Suqiao¹,Zhang Mingyuan²

1.Department of Respirology and Critical Medicne, Beijing Chaoyang Hospital, Capital Medical University,Beijing Institute of Respiratory Medicine, Beijing 100020,China;
2.Department of Respiratory Medicine,Tianjin Haihe Hospital,Tianjin 300350,China

Received:2016-01-15 Online:2016-04-05 Published:2016-04-18
Contact: Yang Yuanhua,Email: yyh1031@sina.com

摘要/Abstract

摘要： 在我国,新型抗凝药物正逐渐应用于静脉血栓栓塞症(VTE)的治疗中,主要包括Ⅹa因子抑制剂和Ⅱa因子抑制剂两大类。本文主要对各种新型抗凝药物治疗VTE的临床研究结果、使用方法及使用注意事项等方面进行阐述,以利于临床更好地使用这些药物,从而达到最佳治疗效果。

关键词: 静脉血栓形成, 抗凝, 抗凝血酶Ⅲ, 出血

Abstract: In China, the new anticoagulants, which mainly include two categories: factor Ⅹa inhibitors and factor Ⅱa inhibitors, have been gradually applied in the treatment of venous thromboembolism (VTE). This article illustrates the results of clinical study, application methods and cautions of VTE treatments that employed various new anticoagulants for better clinical using of these drugs and getting best effect of therapy.

Key words: venous thrombosis, anticoagulants, antithrombin Ⅲ, hemorrhage

中图分类号:

R543.6

杨媛华, 杨苏乔, 张明园. 新型抗凝药物及其治疗静脉血栓栓塞症的临床应用[J]. 临床荟萃, 2016, 31(4): 352-354.

Yang Yuanhua, Yang Suqiao,Zhang Mingyuan. New anticoagulants and clinical application of venous thromboembolism[J]. Clinical Focus, 2016, 31(4): 352-354.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.04.002

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I4/352

参考文献

[1] Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS)[J]. Eur Heart J, 2014,35(43): 3033-3073.
[2] Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012,141(2 Suppl): e120S-51S.
[3] Bergqvist D. Review of fondaparinux sodium injection for the prevention of venousthromboembolism in patients undergoing surgery[J]. Vasc Health Risk Manag, 2006,2(4): 365-370.
[4] Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism[J]. N Engl J Med, 2003,349(18): 1695-1702.
[5] Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venousthrombosis: a randomized trial[J]. Ann Intern Med,2004,140(11): 867-873.
[6] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363(26): 2499-2510.
[7] Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012,366(14): 1287-1297.
[8] Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism[J]. N Engl J Med, 2013,369(9): 799-808.
[9] Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J]. N Engl J Med, 2013,369(15): 1406-1415.
[10] Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis[J]. Circulation, 2014,129(7): 764-772.
[11] Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism[J]. N Engl J Med, 2013,368(8): 709-718.
[12] Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease[J]. N Engl J Med, 2007,357(11): 1094-1104.
[13] Limone BL, Hernandez AV, Michalak D, et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials[J]. Thromb Res, 2013,132(4): 420-426.
[14] Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace,2013, 15(5): 625-651.
[15] Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study[J]. Clin Pharmacokinet, 2010,49(4): 259-268.
[16] 许欣, 杜军. 急性肺栓塞症的诊治进展[J]. 临床荟萃,2013,28 (6): 699-702.

新型抗凝药物及其治疗静脉血栓栓塞症的临床应用

New anticoagulants and clinical application of venous thromboembolism

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	刘蕾, 李明武, 万荣. 肺结核合并肺栓塞患者实验室指标的诊断价值[J]. 临床荟萃, 2024, 39(2): 134-139.
[3]	刘岩, 刘琼, 梁晓梅, 刘冰. 以发热为主要症状的自发性肾出血继发感染1例并文献复习[J]. 临床荟萃, 2023, 38(9): 823-826.
[4]	高福生, 张川, 展玉涛. 经内镜逆行性胰胆管造影术后并发症相关影响因素分析及防治进展[J]. 临床荟萃, 2023, 38(6): 550-553.
[5]	辛在娥. 误诊为脑膜炎的蛛网膜下腔出血1例及文献复习[J]. 临床荟萃, 2023, 38(5): 448-450.
[6]	马明福, 魏志国, 何铁英. 急性胰腺炎并发胰腺假性囊肿危险因素的meta分析[J]. 临床荟萃, 2023, 38(4): 293-301.
[7]	周慧贤, 周亚青, 郭甘霖, 崔炜. 左心室血栓治疗的系统回顾及meta分析[J]. 临床荟萃, 2023, 38(2): 101-110.
[8]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[9]	李姮, 李永辉, 孙小强, 王琳, 何峰. 窦性心律慢性心力衰竭患者抗凝治疗安全性及有效性系统评价[J]. 临床荟萃, 2022, 37(5): 406-411.
[10]	周子涵, 崔炜. 心血管系统常用药物对新型冠状病毒肺炎感染风险及不良预后的影响[J]. 临床荟萃, 2022, 37(10): 869-888.
[11]	李文哲, 商进春, 李春梅, 田芬, 李君, 崔莉, 邢广群. 尿毒症规律血液透析患者脑出血危险因素分析[J]. 临床荟萃, 2022, 37(1): 20-25.
[12]	史晓英, 何洪真, 郭星, 吕佩源. 脑白质高信号与自发性脑出血[J]. 临床荟萃, 2021, 36(6): 562-565.
[13]	李文哲, 商进春, 李春梅, 李君, 田芬, 崔莉, 陈怿鹏, 张小凡, 邢广群. 枸橼酸钠抗凝连续性肾脏替代治疗救治尿毒症脑出血患者的优势[J]. 临床荟萃, 2021, 36(5): 425-431.
[14]	张江, 刘春燕, 陶怡凝, 常莉莎. 远隔缺血适应在脑血管疾病中的临床应用研究进展[J]. 临床荟萃, 2021, 36(3): 277-280.
[15]	吴亮, 刘明. 血清免疫球蛋白及补体C3、C4水平与高血压性脑出血患者预后的关系[J]. 临床荟萃, 2021, 36(2): 107-111.